Prevention & lipidsCross-sectional study
Implications of the 2026 Dyslipidemia Guideline for Primary Prevention Statin Therapy
- Cross-sectional study
- nationally representative
- weighted sample
Authors' conclusion
The 2026 dyslipidemia guideline substantially expands the US population recommended for primary prevention statin therapy, predominantly in lower-risk individuals.
Study context
- Population
- Nonpregnant US adults aged 30–79 years without known atherosclerotic cardiovascular disease (ASCVD), NHANES 2017–2023representative of 154.5 million US adults
- Participants
- 4,366 adults
- Exposure
- 2026 vs 2018 lipid guideline statin eligibility
- Outcome
- Changes in eligibility for primary prevention statin therapy, 2026 vs 2018 lipid guidelines
Main finding
As reported in the abstract
Statin eligibility under 2026 guideline
Statin eligible under 2026 guideline: 87.5 million
56.6% (95% CI, 54.2%-58.9%)
Newly statin eligible: 21.5 million
13.9% (95% CI, 12.5%-15.5%)
Observational data: associations, not effects.
Further findings
Mean
| Outcome | Newly statin eligible | Previously eligible |
|---|---|---|
| Mean estimated 10-year ASCVD risk | 3.1% (95% CI 2.7%–3.5%) | 6.1% (95% CI 5.8%–6.4%) |
Statin eligibility by age
- Aged 70–79 years
- More than 93%
- Aged 60–69 years
- 85%
- Aged 30–39 years
- 11%
Baseline categories
- Untreated LDL-C <70 mg/dL
- 5.5% (95% CI, 4.7%-6.6%)
- Currently taking statins
- 17.8% (95% CI, 16.3%-19.5%)
- Eligible independent of risk estimation (LDL-C ≥190 mg/dL, DM or CKD)
- 8.6% (95% CI, 7.6%-9.8%)
- Risk estimation to guide statin decisions
- 68.0% (95% CI, 65.9%-70.0%)
Original publication
Implications of the 2026 Dyslipidemia Guideline for Primary Prevention Statin Therapy. JAMA. Published 18 August 2026. doi:10.1001/jama.2026.11246
Summarised from the published abstract; every number is checked against it